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Background: The current treatment strategy formany patients with varicose veins is endovenous thermal
ablation. The most common forms of this are endovenous laser ablation (EVLA) and radiofrequency
ablation (RFA). However, at present there is no clear consensus on which of these treatments is
superior. The objective of this study was to compare EVLA with two forms of RFA: direct RFA (dRFA;
radiofrequency-induced thermotherapy) and indirect RFA (iRFA; VNUS ClosureFast™).
Methods: Patients with symptomatic great saphenous vein (GSV) incompetence were randomized
to receive EVLA, dRFA or iRFA. Patients were followed up at 2weeks, 6 and 12months. The primary
outcome was GSV occlusion rate. Secondary outcomes included Venous Clinical Severity Score (VCSS),
Aberdeen Varicose Vein Questionnaire (AVVQ) score and adverse events.
Results: Some 450 patients received the allocated treatment (EVLA, 148; dRFA, 152; iRFA, 150). The
intention-to-treat analysis showed occlusion rates of 75⋅0 (95 per cent c.i. 68⋅0 to 82⋅0), 59⋅9 (52⋅1 to 67⋅7)
and 81⋅3 (75⋅1 to 87⋅6) per cent respectively after 1 year (P= 0⋅007 for EVLA versus dRFA, P<0⋅001 for
dRFA versus iRFA, P= 0⋅208 for EVLA versus iRFA). VCSS improved significantly for all treatments with
no significant differences between them. AVVQ scores also improved significantly for all treatments, but
iRFA had significantly better scores than dRFA at 12months. Significantly more adverse events were
reported after treatment with EVLA (103) than after dRFA (61) and iRFA (65), especially more pain.
Conclusion: Primary GSV occlusion rates were better after iRFA and EVLA than dRFA. All three
interventions were effective in improving the clinical severity of varicose veins at 1 year.
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Introduction
Varicose veins of the leg, a sign of chronic venous disease,
affect around 25–40 per cent of the adult population1–3.
The aim of treatment is to reduce symptoms, but also to
prevent long-term complications of chronic venous insuf-
ficiency such as leg ulceration.
The treatment of choice for an incompetent great
saphenous vein (GSV) is endovenous thermal ablation4–6.
There are several ways to ablate the vein, of which laser
and radiofrequency are the most frequently used; however,
none of the guidelines state which technique is preferred.
Although several studies7–11 have compared these two
treatments, it is still unclear whether endovenous laser
ablation (EVLA) is superior to radiofrequency ablation
(RFA).
The objective of this study was to compare the efficacy of
EVLA and two different forms of RFA: direct RFA (dRFA;
radiofrequency-induced thermotherapy) and indirect RFA
(iRFA; VNUS ClosureFast™; VNUS Medical Techno-
logies, St Jose, California, USA). A three-arm,
double-blind RCT was undertaken comparing these
treatments for GSV incompetence based on occlusion
rates after 1 year, with the hypothesis that EVLA would be
superior to both dRFA and iRFA.
Methods
A single-centre, double-blind, three-arm, superiority RCT
was carried out at the Phlebology Centre, Isala, Zwolle,
between October 2010 and January 2014. The study
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protocol was reviewed and approved by the local medical
ethics committee (NL27871.075.10).
Patients were randomized to EVLA, dRFA or iRFA by
stratified block randomization using a computer program.
In total, three physicians (2 dermatologists and 1 vascular
surgeon) performed the interventions. Each physician had
their own block randomization resulting in an equal distri-
bution of patients among the three treatment groups.
Patients and observers were blinded to the treatment
allocation. During treatment, the device was covered such
that the patient would not be able to see it. Patients were
not allowed to have been treated previously by any of the
techniques used here so they would not be able to recog-
nize the sound of the device. The EVLA protocol was used
for all patients, which meant they were all asked to wear
protective glasses. No information on the technique used
was documented in the electronic patient file, only tech-
nical information such as length of the treated segment.
The physician who evaluated the patient at follow-up vis-
its was different from the one who treated the patient, and
was therefore unaware of the technique used. Similarly, the
assistants who helped with completion of questionnaires
had not been present at the procedure.
Adult patients (aged 18 years and over) with a symp-
tomatic incompetent GSV over a length of at least 15 cm,
and with a diameter of 3mm or more and no larger than
15mm, were eligible to participate. GSV incompetence
was defined as reflux lasting more than 0⋅5 s on colour
duplex ultrasound imaging (DUS). Reasons for exclusion
were: concomitant ipsilateral small saphenous vein (SSV)
incompetence, history of deep vein thrombosis (DVT) in
the same leg, active superficial vein thrombosis (SVT)
in the GSV, history of surgical or endovenous treatment
or ultrasound-guided foam sclerotherapy of the GSV or
SSV, pregnancy, BMI 40 kg/m2 or more, proven periph-
eral artery occlusive disease (ankle : brachial pressure index
below 0⋅8), poor overall health, immobility, and a known
coagulation disorder resulting in increased coagulation.
For patients with bilateral GSV incompetence, only one
leg was included in the study.
In this study the incompetent GSV was treated with
either EVLA, dRFA or iRFA.
All endovenous treatments were performed under DUS
as described elsewhere12,13. For all techniques, the vein
was accessed by puncturing the vein with a 16- or 18-Fr
needle at the lowest point of GSV incompetence, but not
more than 10–15 cm below the knee. After gaining vein
access, a guidewire was passed through the needle up to the
saphenofemoral junction (SFJ) over which an introducer
sheath was passed. The guidewire was removed, and either
the laser, dRFA or iRFA fibre/catheter was introduced and
positioned approximately 1–2 cm from the SFJ. Tumes-
cent anaesthetic solution (0⋅5mg adrenaline (epinephrine),
4⋅2mg bicarbonate and 35ml lidocaine diluted in 500ml
0⋅9 per cent saline) was administered under DUS guidance
into the saphenous compartment using a mechanical infu-
sion pump.
For EVLA, a 980-nm diode laser (Biolitec ELVeS™;
Biolitec, Vienna, Austria) was used with a bare-tip fibre
and power of 10W. The laser was pulled back con-
tinuously, attempting to administer 60 J/cm. The dRFA
catheter (Celon, Teltow, Germany) was also withdrawn
in continuous mode and was monitored using the inbuilt
acoustic impedance feedback mechanism. If feedback sig-
nalled accumulation of coagulum on the applicator tip, the
procurve was removed, cleaned and reinserted to continue
treatment. The VNUS Closure Fast™ contained a 7-cm
heating element. Two cycles of 20 s were administered for
the first 7 cm close to the SFJ and only one cycle for the
rest of the incompetent GSV. Possible tributaries were not
treated, to prevent contamination of the results.
All patients were evaluated by physical examination and
DUS at time of inclusion, during treatment, and 2weeks,
6 and 12months after treatment.
The primary outcome of the trial was the rate of occlu-
sion after 12months of follow-up. The following terms
were used to evaluate the treated GSV: occlusion, par-
tial occlusion and no occlusion. The GSV was assessed at
three points in the leg: proximal (close to the SFJ), medial
(halfway along the upper leg) and distal (lowest point of
treatment). Occlusion was defined as absence of flow in a
non-compressible GSV or an absent GSV at all three mea-
surement points. If there was a segment of compressible
GSV with or without flow (antegrade flow or reflux) in one
or two of the measurement points, it was rated as partial
occlusion. If the treated GSV was still completely open at
all three measurement points, it was classified as no occlu-
sion and treatment failure. The analysis comprised evalu-
ation of anatomical success (complete occlusion) versus no
anatomical success (partial and no occlusion) as the aim of
treatment was to occlude the GSV completely.
Clinical signs of chronic venous disease were assessed
by means of the Clinical Etiologic Anatomic Pathophys-
iologic (CEAP) classification14 and the Venous Clinical
Severity Score (VCSS)15 at baseline, and 6 and 12months
after treatment. The Aberdeen Varicose Vein Question-
naire (AVVQ)15 was used to assess disease-specific quality
of life before, and 6 and 12months after treatment. At all
follow-up visits, the occurrence of the following adverse
events was registered: pain, haematoma/ecchymosis, DVT,
SVT, infection, induration, hyperpigmentation, skin burn,
dysaesthesia, nerve damage, pulmonary embolism and
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Fig. 1 CONSORT flow chart showing patient inclusion
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*One patient was excluded as the incompetent vein was actually a tributary and not the great saphenous vein. EVLA, endovenous laser ablation; dRFA,
direct radiofrequency ablation; iRFA, indirect radiofrequency ablation; PP, per protocol; ITT, intention to treat; LOCF, last observation carried forward.
‘other’. Pain was evaluated using a visual analogue scale
(VAS) ranging from 0 (least) to 10 (most) at baseline, dur-
ing treatment and administration of tumescent anaesthesia,
and throughout the first 14 days after treatment. Patients
were also asked to register the use of pain medication
during those 14 days.
To assess patient satisfaction after treatment, patients
were asked if they were satisfied with the treatment they
received (satisfied, somewhat satisfied, somewhat unsatis-
fied, unsatisfied) and if they would choose that treatment
again (yes, probably, probably not, no).
Statistical analysis
The sample size calculation for this superiority design
determined that 408 patients (136 per arm) were needed
to detect a 10 per cent difference in occlusion rate after
1 year between EVLA and both RFA groups. Possible
loss to follow-up of 10 per cent was taken into account,
resulting in 450 patients needed for inclusion (150 per
treatment arm).
Categorical data were analysed using the χ2 or Fisher’s
exact test. In the event of a statistically significant
difference (P< 0⋅050), the three treatments were com-
pared separately, with P< 0⋅016 considered statistically
significant. None of the nominal data were distributed
normally, so non-parametric tests were used. First,
the Kruskal–Wallis test was used to identify possi-
ble significant differences between the three treatment
groups (P< 0⋅050). If the difference was significant, the
Mann–WhitneyU test was used to analyse the three treat-
ment groups separately, with P< 0⋅016 taken to indicate
statistical significance. VAS scores during the first 2weeks
after treatment were analysed by means of multivariable
analysis.
All analyses were done in SPSS® version 24 (IBM,
Armonk, New York, USA) and RStudio® version 1.1.453
(RStudio, Boston, Massachusetts, USA).
Results
Some 451 patients were randomized in this study, of whom
450 received the allocated treatment (Fig. 1). One patient
was excluded because the vein to be treated was actu-
ally a tributary rather than the GSV, so this patient did
not meet the inclusion criteria. The baseline character-
istics for all patients can be found in Table 1. All 450
patients were included in the intention-to treat (ITT) and
last-observation-carried-forward (LOCF) analyses. For
per-protocol (PP) analyses, a total of 393 patients were
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Table 1 Baseline characteristics
EVLA (n=148) dRFA (n=152) iRFA (n=150)
Patient demographics
Age (years)* 51⋅1(13⋅6) 52⋅6(13⋅4) 49⋅3(13⋅9)
Sex ratio (F :M) 97 : 51 103 : 49 105 : 45
Limb characteristics
Left side 62 (41⋅9) 72 (47⋅4) 71 (47⋅3)
C class (CEAP classification)
C2 51 (34⋅5) 46 (30⋅3) 49 (32⋅7)
C3 76 (51⋅4) 88 (57⋅9) 82 (54⋅7)
C4 14 (9⋅5) 15 (9⋅9) 17 (11⋅3)
C5 3 (2⋅0) 1 (0⋅7) 2 (1⋅3)
C6 3 (2⋅0) 2 (1⋅3) 0 (0)
Missing 1 (0⋅7) 0 (0) 0 (0)
AVVQ† 9⋅39 (6⋅57–13⋅38) 8⋅14 (4⋅36–14⋅26) 7⋅69 (4⋅82–11⋅53)
VCSS† 4 (3–6) 4 (3–5) 4 (3–5)
GSV diameter (supine position) (mm)†
Proximal 7⋅8 (6⋅1–9⋅7) 7⋅6 (6⋅2–9⋅3) 7⋅3 (6⋅1–9⋅5)
Medial 5⋅8 (4⋅5–7⋅1) 5⋅5 (4⋅5–7⋅4) 5⋅4 (4⋅5–7⋅1)
Distal 5⋅4 (4⋅3–6⋅9) 5⋅6 (4⋅6–7⋅0) 5⋅4 (4⋅3–6⋅5)
Treatment characteristics
Length of treated segment (cm)* 35⋅5(10⋅7) 37⋅3(10⋅2) 36⋅6(10⋅3)
Duration of treatment (min)† 19⋅5 (15⋅5–23⋅1) 16⋅2 (12⋅6–19⋅5) 17⋅0 (13⋅1–20⋅0)
Energy used (J/cm)* 60⋅1(9⋅85) – –
No. of cycles* – 6⋅85(1⋅71) –
Values in parentheses are percentages unless indicated otherwise; values are *mean(s.d.) and †median (i.q.r.). EVLA, endovenous laser ablation; dRFA,
direct radiofrequency ablation; iRFA, indirect radiofrequency ablation; CEAP, Clinical Etiologic Anatomic Pathophysiologic; AVVQ, Aberdeen Varicose
Vein Questionnaire; VCSS, Venous Clinical Severity Score; GSV, great saphenous vein.
analysed; 57 did not complete the 1-year follow-up owing
to early failure or loss to follow-up.
Twenty-two patients showed no occlusion at 2weeks or
6months (primary treatment failure) and received addi-
tional treatment with iRFA, for practical reasons. It was
deemed unethical to let these patients complete 1-year
follow-up before retreatment, so they received further
treatment shortly after initial treatment failure had been
established. It was decided to exclude these patients from
further follow-up. However, for ITT analysis, the results
after retreatment with iRFA would be included in the orig-
inal treatment group (EVLA or dRFA). For the ITT ana-
lysis, these were considered as treatment failures, meaning
that their data were imputed as ‘no occlusion’ for the pri-
mary outcome, and no improvement compared with base-
line for VCSS and AVVQ scores.
Thirty-one other patients had data missing at 12months
owing to loss to follow-up. For the ITT analysis, these
patients were also considered as treatment failures, with
missing data imputed as described above. A sensitivity
analysis for the primary and secondary (VCSS and AVVQ
scores) outcomes was performed, in which missing values
were imputed with the last available value, based on the
LOCF method. A third analysis using the PP principle was
also undertaken.
Anatomical success
In ITT analysis, GSV occlusion rates were 75⋅0 (95 per
cent c.i. 68⋅0 to 82⋅0), 59⋅9 (52⋅1 to 67⋅7) and 81⋅3 (75⋅1
to 87⋅6) per cent 1 year after EVLA, dRFA and iRFA
respectively (Table 2). Both EVLA (P= 0⋅007) and iRFA
(P< 0⋅001) had significantly higher success rates than
dRFA. Results for the LOCF and PP analyses were com-
parable, with success rates of 79⋅1 and 86⋅0 per cent
respectively for EVLA, 66⋅4 and 72⋅2 per cent for dRFA,
and 87⋅3 and 88⋅4 per cent for iRFA (Table 2). In both
these sensitivity analyses, a significant difference was
found between dRFA and iRFA (P< 0⋅001 for LOCF and
P= 0⋅001 for PP), and only between EVLA and dRFA in
the PP analysis (P= 0⋅008).
At 6-month follow-up, in the ITT analysis, the VCSS
had improved to a median of 2 in all groups, which
continued to 12months (Table 3). Results were similar in
the LOCF and PP analysis. For all treatment groups and
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Table 2 Rates of occlusion
Intention to treat LOCF Per protocol
Complete
occlusion
No/partial
occlusion P*
Complete
occlusion
No/partial
occlusion P*
Complete
occlusion
No/partial
occlusion P*
EVLA 111 (75⋅0) 37 (25⋅0) 0⋅007 versus dRFA 117 (79⋅1) 31 (20⋅9) 0⋅019 versus dRFA 111 (86⋅0) 18 (14⋅0) 0⋅008 versus dRFA
dRFA 91 (59⋅9) 61 (40⋅1) <0⋅001 versus iRFA 101 (66⋅4) 51 (33⋅6) <0⋅001 versus iRFA 91 (72⋅2) 35 (27⋅8) 0⋅001 versus iRFA
iRFA 122 (81⋅3) 28 (18⋅7) 0⋅208 versus EVLA 131 (87⋅3) 19 (12⋅7) 0⋅063 versus EVLA 122 (88⋅4) 16 (11⋅6) 0⋅586 versus EVLA
Values in parentheses are percentages. LOCF, last observation carried forward; EVLA, endovenous laser ablation; dRFA, direct radiofrequency ablation;
iRFA, indirect radiofrequency ablation. *χ2 test.
Table 3 Intention-to-treat analysis of Venous Clinical Severity
Score and Aberdeen Varicose Vein Questionnaire scores
EVLA dRFA iRFA
VCSS
Baseline 4 (3–6) 4 (3–5) 4 (3–5)
6months 2 (1–3) 2 (1⋅25–3) 2 (1–3)
12months 2 (1–3) 2 (1–4) 2 (1–3)
AVVQ score
Baseline 9⋅39 (6⋅57–13⋅38) 8⋅14 (4⋅36–14⋅26) 7⋅69 (4⋅82–11⋅53)
6months 2⋅64 (0⋅69–6⋅69) 2⋅46 (0⋅69–7⋅74) 1⋅74 (0⋅65–4⋅63)
12months 2⋅57 (0⋅53–7⋅36) 3⋅74 (0⋅86–9⋅36) 1⋅92 (0⋅34–5⋅74)
Values are median (i.q.r.). EVLA, endovenous laser ablation; dRFA,
direct radiofrequency ablation; iRFA, indirect radiofrequency ablation;
VCSS, Venous Clinical Severity Score; AVVQ, Aberdeen Varicose Vein
Questionnaire.
sensitivity analyses this improvement was statistically sig-
nificant (P< 0⋅001), but no significant differences were
found between the three treatments.
Median AVVQ scores at baseline ranged from 7⋅69 to
9⋅39 and had improved significantly after 6months for
all three treatments (P< 0⋅001) (Table 3). This improve-
ment was still present after 12months. For this analysis, a
significant difference was found between dRFA and iRFA
(P= 0⋅009). The LOCF analysis showed slightly better
results, with median scores of 2⋅33 (i.q.r. 0⋅52–5⋅75) for
EVLA, 3⋅21 (0⋅86–9⋅33) for dRFA and 1⋅57 (0⋅34–4⋅94)
for iRFA after 12months. Again, a significant differ-
ence was found between dRFA and iRFA (P= 0⋅006),
but there was no significant difference for EVLA versus
dRFA or iRFA. Median scores in the PP analysis were
2⋅28 (0⋅52–5⋅46) for EVLA, 2⋅71 (0⋅60–7⋅06) for dRFA
and 1⋅57 (0⋅3–5⋅08) for iRFA after 12months, with no
significant differences between the three treatment groups.
Adverse events
The occurrence of adverse events was registered at all
follow-up visits. No severe adverse events such as DVT or
pulmonary embolism were reported during the study. One
Fig. 2 Adverse events in each treatment group
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Other
EVLA, endovenous laser ablation; dRFA, direct radiofrequency ablation;
iRFA, indirect radiofrequency ablation; SVT, superficial vein thrombosis;
DVT, deep vein thrombosis; PE, pulmonary embolism.
or more adverse events in the first 2weeks after treatment
were reported by 103 of 146 patients (70⋅5 per cent) in the
EVLA group, 61 of 146 (41⋅8 per cent) in the dRFA group
and 65 of 150 in the iRFA group (43⋅3 per cent). The
differences betweenEVLA and dRFA, andEVLA and iRFA
were statistically significant (P< 0⋅001) (Fig. 2). Pain was
the most frequently reported adverse event in all three
groups, but significantly more after EVLA than after dRFA
and iRFA (both P= 0⋅007).
Pain and patient satisfaction
During administration of tumescent anaesthetic, VAS
scores were similar in all treatment groups, with median
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values of 2⋅3 (i.q.r. 0⋅8–3⋅7) for EVLA, 2⋅7 (1⋅4–2⋅9)
for dRFA and 2⋅7 (1⋅4–4⋅4) for iRFA (P= 0⋅115). Median
pain scores during treatment were 0⋅2 (0–0⋅8), 0⋅2 (0–1⋅1)
and 0⋅6 (0⋅1–2⋅6) respectively. Scores were significantly
higher for iRFA than for either EVLA (P< 0⋅001) or dRFA
(P= 0⋅001).
VAS scores reported by patients during the first 14 days
after treatment showed different patterns in the three treat-
ment groups. Patients treated with EVLA reported higher
pain scores directly after treatment than those in the other
groups, with a mean(s.d.) of 2⋅2(1⋅9), but this improved
over time with an intercept of 0⋅1. After dRFA, the pain
scores were initially low, with a mean of 0⋅8(0⋅9), and
decreased slightly over time with an intercept of 0⋅04. For
patients treated with iRFA, the pain scores were initially
low (mean VAS 0⋅4(0⋅0)), but increased slightly over time
with an intercept of 0⋅1. Comparing these patterns over
time, there was no difference between EVLA and dRFA,
but EVLA and iRFA differed significantly (P= 0⋅012).
However, significantly more patients treated with EVLA
used pain medication (95 of 143, 66⋅4 per cent) than
patients treated with dRFA (57 of 149, 38⋅3 per cent) and
iRFA (63 of 148, 42⋅6 per cent) (both P< 0⋅001).
At the first follow-up visit 2weeks after treatment,
patients were asked if they were satisfied with the treat-
ment they received and would choose the same treatment
again. For EVLA, 136 of 145 (93⋅8 per cent) were satisfied
or somewhat satisfied with their treatment, compared with
148 of 150 (98⋅7 per cent) for dRFA and 149 of 150 (99⋅3
per cent) for iRFA. Only the difference between EVLA and
iRFA was statistically significant (P= 0⋅009). Some 90⋅3
per cent of the patients treated with EVLA would choose
the same treatment again, compared with 97⋅3 and 98⋅0
per cent of those who had dRFA and iRFA respectively
(P= 0⋅014 and P= 0⋅005).
Discussion
In this three-arm study, both EVLA and iRFA were signif-
icantly more effective than dRFA in treating GSV incom-
petence 1 year after treatment. Patients treated with EVLA
reported more adverse events, specifically pain, and used
more pain medication after treatment than those who had
dRFA or iRFA. VAS scores during iRFA were significantly
higher than those during EVLA and dRFA, but the dif-
ference of 0⋅4 was not considered clinically relevant. VAS
pain scores during the first 2weeks after treatment were
higher after EVLA than either dRFA or iRFA. Curiously,
the pain scores after iRFA seemed to increase slightly dur-
ing this interval. However, the pain scores varied widely
and too few patients registered pain scores for the full
14 days to draw reliable conclusions based on this ana-
lysis. VCSS improved significantly in all groups, with no
significant differences between the three treatments after
1 year. AVVQ scores also improved significantly after all
three treatments; however, both the ITT and LOCF ana-
lysis showed significantly better AVVQ scores after iRFA
than dRFA.
Several non-blinded studies have compared the efficacy
of EVLA, iRFA and dRFA, with inconclusive results. One
meta-analysis7 and a systematic review16 both suggested
higher occlusion rates for EVLA than for iRFA, with less
pain after iRFA. The results of a four-arm RCT17 com-
paring EVLA, iRFA, ultrasound-guided foam sclerother-
apy and conventional surgery were similar to those of the
present study, with comparable occlusion rates for EVLA
and iRFA, but also more pain after EVLA.
A plausible explanation for the large number of failures
in the dRFA group could be the fact that this technique
requires steps that are different from those in both EVLA
and iRFA, which are relatively similar in how they are con-
ducted. With the dRFA technique, it is often necessary to
remove the wire and clean it one or more times, after which
treatment is continued. This probably makes treatment
with dRFAmore prone to error and it requiresmore experi-
ence. One of the physicians had less experience with dRFA
before the study than the other two. This could explain why
this physician had around 30 failures in the dRFA group,
whereas the other two had around ten failures each.
Patients who had EVLA were less satisfied with their
treatment, and fewer patients would choose the treatment
again, compared with those treated with dRFA and iRFA.
This may be because the patients who had EVLA experi-
encedmore adverse events, and specifically more pain, than
patients in the RFA groups.
This study has some limitations. Fifty-seven of the 450
patients did not complete the 1-year follow-up, 22 owing to
early treatment failure resulting in exclusion from further
follow-up. It would have been interesting to determine the
influence of early failure on outcomes such as VCSS and
AVVQ scores, but it was deemed unethical to allow these
patients to complete follow-up before retreatment. These
patients were excluded from follow-up, but their data were
included in the ITT and LOCF analyses. It should also
be noted that a 980-nm fibre was used for EVLA, whereas
1470 nm is currently the preferred wavelength as it might
be associated with less postoperative pain18.
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